Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN KINGREY

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1689863953
CMS profile
496940
Location
OKLAHOMA CITY, OK

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$60,305.05

116 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 116 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN KINGREY

NPI 1689863953 · CMS profile ID 496940

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

OKLAHOMA CITY, OK

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 116 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1689863953?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN KINGREY, NPI 1689863953, CMS profile ID 496940. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 116 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1689863953?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JOHN KINGREY, NPI 1689863953, CMS profile ID 496940. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 116 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1689863953?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JOHN KINGREY, NPI 1689863953, CMS profile ID 496940, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 116 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1689863953?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

116 matching records · $60,305.05 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 116 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 116.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
United Therapeutics Corporation $59.9806/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050965405 CMS
United Therapeutics Corporation $395.9606/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050970377 CMS
United Therapeutics Corporation $684.1006/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050970705 CMS
United Therapeutics Corporation $1,040.0006/21/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050970895 CMS
Inogen, Inc. $15.0306/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040273623 CMS
Actelion Pharmaceuticals US, Inc. $8.1406/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988590409 CMS
Actelion Pharmaceuticals US, Inc. $14.3006/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988590413 CMS
Actelion Pharmaceuticals US, Inc. $3,030.0006/14/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988590355 CMS
Boston Scientific Corporation $22.4006/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022526839 CMS
Actelion Pharmaceuticals US, Inc. $114.6906/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988590351 CMS
Bayer Healthcare Pharmaceuticals Inc. $385.0005/25/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000685061 CMS
United Therapeutics Corporation $6,200.0005/24/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050971969 CMS
Actelion Pharmaceuticals US, Inc. $75.1005/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988590405 CMS
United Therapeutics Corporation $44.9005/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050964607 CMS
Sandoz Inc. $44.9505/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1028944505 CMS
Actelion Pharmaceuticals US, Inc. $106.9005/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988590387 CMS
Actelion Pharmaceuticals US, Inc. $40.7405/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988590401 CMS
Merck Sharp & Dohme LLC $89.6005/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048398577 CMS
Actelion Pharmaceuticals US, Inc. $16.6605/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988590375 CMS
Actelion Pharmaceuticals US, Inc. $3.7405/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988590371 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $28.5105/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996536151 CMS
Bayer Healthcare Pharmaceuticals Inc. $4,270.0005/05/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000686097 CMS
United Therapeutics Corporation $5.3705/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050946199 CMS
United Therapeutics Corporation $23.2105/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050957161 CMS
United Therapeutics Corporation $23.2105/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050957163 CMS
United Therapeutics Corporation $24.0005/05/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050958315 CMS
United Therapeutics Corporation $39.7705/05/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050964221 CMS
United Therapeutics Corporation $42.4805/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050964405 CMS
United Therapeutics Corporation $43.8405/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050964573 CMS
United Therapeutics Corporation $52.8705/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050965157 CMS
United Therapeutics Corporation $4.3305/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050946107 CMS
United Therapeutics Corporation $8.2405/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050946521 CMS
United Therapeutics Corporation $39.5205/04/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050964209 CMS
United Therapeutics Corporation $75.5105/04/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050966021 CMS
United Therapeutics Corporation $79.1105/04/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050966189 CMS
United Therapeutics Corporation $315.2705/04/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050970223 CMS
Johnson & Johnson Health Care Systems Inc. $13.1405/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991347103 CMS
Bayer Healthcare Pharmaceuticals Inc. $20.0205/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000676343 CMS
Actelion Pharmaceuticals US, Inc. $3,030.0004/26/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988590347 CMS
Actelion Pharmaceuticals US, Inc. $16.0604/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988590367 CMS
United Therapeutics Corporation $3,400.0004/26/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050971679 CMS
Actelion Pharmaceuticals US, Inc. $149.7004/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988590325 CMS
Actelion Pharmaceuticals US, Inc. $108.2104/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988590337 CMS
Insmed, Inc. $29.3004/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 978789043 CMS
Actelion Pharmaceuticals US, Inc. $44.2804/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988590343 CMS
United Therapeutics Corporation $335.7004/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050970283 CMS
United Therapeutics Corporation $419.9804/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050970407 CMS
United Therapeutics Corporation $1,025.9404/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050970891 CMS
Actelion Pharmaceuticals US, Inc. $3,535.0004/05/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988590321 CMS
United Therapeutics Corporation $101.5704/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050967325 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $37,651.34 75
PY2020 $23,986.19 28
PY2021 $38,451.07 54
PY2022 $60,467.08 86
PY2023 $60,305.05 116
PY2024 $61,835.64 93
PY2025 $49,481.58 66

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $606,215.02 45
PY2024 Principal investigator $461,986.83 23
PY2023 Principal investigator $442,655.90 25
PY2022 Principal investigator $122,020.59 35
PY2021 Principal investigator $63,022.14 25
PY2020 Principal investigator $329,083.22 35
PY2019 Principal investigator $55,490.32 34

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

45 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $118,580.19 12/31/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A Phase 3, Randomized Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients No dispute reported 06/30/2026 1232936582
Principal investigator 1 Merck Sharp & Dohme LLC $323,216.40 12/31/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy for the Treatment of PAH No dispute reported 06/30/2026 1232938826
Principal investigator 1 United Therapeutics Corporation $1,300.00 12/24/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242381456
Principal investigator 1 United Therapeutics Corporation $6,476.02 12/24/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242381486
Principal investigator 1 Janssen Research & Development, LLC $581.45 12/12/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175400811
Principal investigator 1 United Therapeutics Corporation $829.24 12/10/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242381448
Principal investigator 1 United Therapeutics Corporation $975.00 11/26/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242381450
Principal investigator 1 United Therapeutics Corporation $6,476.02 11/12/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242381484
Principal investigator 1 Janssen Research & Development, LLC $714.00 10/30/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175400788
Principal investigator 1 United Therapeutics Corporation $223.53 10/22/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242381438
Principal investigator 1 United Therapeutics Corporation $2,015.00 10/22/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242381464
Principal investigator 1 United Therapeutics Corporation $4,169.70 10/22/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242381478
Principal investigator 1 Janssen Research & Development, LLC $1,379.00 10/02/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175400800
Principal investigator 1 United Therapeutics Corporation $2,990.00 09/10/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242381470
Principal investigator 1 United Therapeutics Corporation $416.38 08/27/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242381444
Principal investigator 1 United Therapeutics Corporation $4,169.70 08/27/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242381476
Principal investigator 1 United Therapeutics Corporation $10,137.24 08/27/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242381488
Principal investigator 1 Janssen Research & Development, LLC $13,616.12 08/04/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175400794
Principal investigator 1 Janssen Research & Development, LLC $238.00 07/28/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175400816
Principal investigator 1 Janssen Research & Development, LLC $140.00 07/28/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175400853
Principal investigator 1 United Therapeutics Corporation $311.50 07/23/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242381440
Principal investigator 1 United Therapeutics Corporation $6,476.02 07/23/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242381482
Principal investigator 1 United Therapeutics Corporation $1,235.00 07/08/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242381454
Principal investigator 1 United Therapeutics Corporation $13,214.51 07/08/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242381490
Principal investigator 1 United Therapeutics Corporation $36,281.24 07/08/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242381494
Principal investigator 1 Janssen Research & Development, LLC $330.08 06/12/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175400828
Principal investigator 1 United Therapeutics Corporation $2,210.00 06/11/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242381466
Principal investigator 1 United Therapeutics Corporation $2,332.79 05/21/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242381468
Principal investigator 1 United Therapeutics Corporation $6,476.02 05/21/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242381480
Principal investigator 1 United Therapeutics Corporation $400.00 04/23/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242381442
Principal investigator 1 United Therapeutics Corporation $1,170.00 04/23/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242381452
Principal investigator 1 Janssen Research & Development, LLC $238.00 03/31/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175400781
Principal investigator 1 Janssen Research & Development, LLC $1,379.00 03/28/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175400804
Principal investigator 1 United Therapeutics Corporation $27.72 03/26/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242381436
Principal investigator 1 United Therapeutics Corporation $520.00 03/26/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242381446
Principal investigator 1 United Therapeutics Corporation $1,929.98 03/26/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242381462
Principal investigator 1 United Therapeutics Corporation $3,769.70 03/26/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242381474
Principal investigator 1 Janssen Research & Development, LLC $700.00 03/07/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175400841
Principal investigator 1 United Therapeutics Corporation $1,755.00 02/26/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242381460
Principal investigator 1 United Therapeutics Corporation $3,769.70 02/26/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242381472
Principal investigator 1 Janssen Research & Development, LLC $1,280.45 02/13/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175400847
Principal investigator 1 United Therapeutics Corporation $1,625.00 01/29/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242381458
Principal investigator 1 United Therapeutics Corporation $19,471.32 01/29/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242381492
Principal investigator 1 Janssen Research & Development, LLC $476.00 01/27/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175400822
Principal investigator 1 Janssen Research & Development, LLC $193.00 01/27/2025 Covered Recipient Teaching Hospital
Integris Baptist Medical Center
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175400834